iCoat Medical’s product portfolio addresses several health issues that are connected to ischemia reperfusion injury. The table below shows what stage each product candidate has reached in the development cycle.
Trials
Finalized:
- ATMIRe – Phase 1/2a (First-in-Human) Double-Blind, Placebo-Controlled, Randomized, Single-Center Trial to Evaluate the Safety and Tolerability of iCM012 solution, 2 mg/mL for ex vivo treatment of preserved kidneys to minimize ischemia-reperfusion injury and thereby improve short- and long-term outcomes after kidney transplantation.
Patient enrollment was completed in May 2023, and the clinical report including 3 months of safety data was completed in December 2023. Follow-up 12 months of safety data was made available during 2024.
In planning:
- EMPIRe – Phase 2b randomized, placebo-controlled, double-blind, Multicenter trial to assess the efficacy and safety of ex vivo allograft administration of iCM012 solution 2 mg/mL to improve allograft function in recipients of donation after circulatory death kidneys. Expected start: second half of 2024.
For further information, see the press releases.
Pharmaceutical products
Candidate / Project
Usage area
Research
Preclinical studies
Clinical preparation
Phase I/IIa
Phase 2b
Expected next step
iCoat Medical’s technology platform
iCM012
Kidney transplantation
CTA application 2024
Other solid organs
Under assessment for next steps
iCM020
iCM012
iCM023
(1st, 2nd, 3rd generation molecules)
iCM012
iCM023
(1st, 2nd, 3rd generation molecules)
Open heart surgery
Pre-clinical studies ongoing
Cell therapies
Ongoing
research
research
Myocardial infarction
Stroke
Completed
Ongoing
Planning
